Sintalica Bioscience

Sintalica is a Canadian drug discovery biotech focused on psychedelic-derived therapeutics for neuroinflammatory and neurodegenerative disorders. The company has emphasized psilocybin and other tryptamine derivatives, including proprietary non-hallucinogenic analogs designed to improve safety, stability, bioavailability, and anti-inflammatory activity. Its research activities have been conducted through an Italian subsidiary and collaborations with the University of Messina and the University of Niccolò Cusano. Sintalica appears to have remained operational as an acquired subsidiary after Huxley Health acquired 100% of the company in September 2023. Public materials indicate the company was at the preclinical stage with an early discovery pipeline rather than named clinical assets.